NVS

Novartis AG Sponsored ADR (NVS) | Rumor.io

Novartis

NVS

Attention (50-day avg)0.01%

Attention rank (50-day avg)#412

Bullish sentiment (50-day avg)23%

Price to earnings ratio22.2

Market capitalization279.2B

Earnings per share6.62

Dividend yield (TTM)13%

Revenue (annual)56.7B

Net income (annual)14B

Social

What share of all stock conversation is about NVS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.01% +0.01	0.02% +0.01	0.01% +0

Sep 16

Novartis has acquired Sironax's proprietary brain delivery platform for $125 million, a move that could help the company overcome the blood-brain barrier in its treatments.
Novartis has halted its TREM2 targeting ALS program after a Phase 2 trial failure, marking the company's fourth trial stumble in a month.
Novartis has faced a string of clinical trial failures, including three major setbacks within a single week, which could impact its cardiovascular and other treatment programs.

Generated by AI

Sentiment

Of the messages about NVS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% -100	84.88% +41.41	18.47% -54.95	67.5% -24.1
Bearish	100% new	15.12% -41.41	81.53% +54.95	32.5% +24.1

Bullish· Sep 8

Novartis' growth target may be unattainable without M&A, which could remain a key part of the story for securing management's longer-term mid-single-digit growth aspiration.
The Avidity Biosciences acquisition by $NVS sinks, potentially leading to a gap fill around $133-$135.
Novartis' CEO should consider acquiring companies like Avidity Biosciences, ALT, and SRPT to gain control of the company's future and create value for shareholders.

Bearish· Sep 8

Novartis' ($NVS) del-desiran drug has failed a late-stage trial, missing its primary endpoint and wiping out $20 billion from its market value.
Novartis' ($NVS) second major late-stage trial setback in a matter of days has added pressure on the company, with its shares plummeting nearly 10%.
Novartis' ($NVS) acquisition of Avidity Biosciences for $12 billion may be seen as a costly mistake, with the company's Neuromuscular drug failing in a key study and its peak sales under pressure.

Generated by AI

Topics

Of the messages about NVS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	95.7%	57.06%	48.41%
Analysts	0%	3.23%	16.31%	5.71%
Earnings	0%	0%	0.48%	3.4%
Macro	0%	0%	16.14%	39.31%
Technical Analysis	0%	0%	0.55%	0.86%
Controversies	0%	1.08%	9.45%	2.31%

Earnings· Apr 28

Novartis's Q1 earnings fell short of estimates, with adjusted EPS of $1.99 vs. expected $2.10 and net sales of $13.11B vs. expected $13.36B.
The company's profit was hit by generic competition, which eroded sales of some of its best-selling medicines, including Cosentyx, Kisqali, and Entresto.
Novartis reaffirmed its FY26 guidance, expecting low single-digit growth in net sales and a decline in core operating income.

Analysts· Sep 11

Citigroup upgraded Novartis (NVS) to Buy from Neutral.
Exane BNP Paribas raised Novartis (NVS) to Neutral from Sell.
Novartis (NVS) target price increased to $98.5 by Bank of America.

Announcements· Sep 8

Novartis' del-desiran drug failed to meet its primary endpoint in a Phase 3 trial for myotonic dystrophy type 1, wiping around $20 billion from its market value.
The failure of del-desiran raises serious questions about the strategic rationale behind Novartis' $12 billion Avidity acquisition and the value driver of the drug.
The setback is Novartis' second major late-stage trial failure in a matter of days, and the company's growth target is now perceived as unattainable without further mergers and acquisitions.

Controversies· Jul 2

Novartis has agreed to pay $678 million to settle a long-running case over alleged kickbacks to doctors, resolving speaker program litigation with US authorities.
The settlement follows a court ruling that upheld Amgen's 31-year monopoly on its Enbrel biosimilar, a decision that Novartis had appealed.
The controversy surrounding Novartis' kickback claims has led to a series of settlements, including a previous agreement to pay $51 million+ to resolve allegations that it paid kickbacks through co-pay foundations.

Macro· Jan 6

The US invasion of Greenland could lead to economic sanctions and tariffs, primarily impacting oil, pharmaceuticals, and machinery companies.
Stocks in oil companies, Boeing, Caterpillar, and GE may be heavily affected by such sanctions, while pharmaceutical companies like Pfizer and Eli Lilly may be spared initially.
The potential shift towards European independence from the US could be beneficial for companies like Novartis, Roche, Sanofi, Biontech, Bayer, and FMC.

Generated by AI

Community

Of the messages about NVS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	58.82%	23.71%	54.74%	19.49%
Newcomers	41.18%	76.29%	45.26%	80.51%

Regulars· Sep 10

Major shareholder Artisan Partners is calling for a board shake-up at Novartis due to recent drug trial setbacks, citing failures in acquisitions and a lackluster deal team.
The recent failure of Novartis' Lp(a) trial has raised concerns about the company's ability to reduce cardiovascular outcomes, with LabCorp highlighting the importance of the Lp(a) biomarker.
Novartis could be interested in acquiring CATX, a company that develops a therapy targeting the same receptor as Novartis' established treatment Lutathera, potentially offering stronger tumor killing with a shorter radiation path.

Newcomers· Sep 10

Novartis ($NVS) suffered a record weekly drop after a string of Phase 3 trial setbacks, including a muscle wasting disorder, raising questions about corporate governance and the company's ability to allocate capital effectively.
The recent failure of Novartis' lead drug del-desiran in Phase 3 trials has raised concerns about the company's pipeline value and the potential impact on its market value.
A major Novartis shareholder has called for changes to the company's board to improve corporate governance, and some analysts are now viewing the company's stock as a "capital-allocation story" rather than a traditional drug story.

Generated by AI

CAS, a division of the American Chemical Society, today announced a collaboration with Novartis Biomedical Research focused on enhancing reaction data accessibility and supporting AI-enabled research. The initiative will leverage CAS unique scientific data curation expertise and science-smart technology to give Novartis researchers integrated, searchable access to proprietary experimental reaction data alongside more than 160 million+ scientist-curated reactions from the authoritative CAS Conten

23h agoYahoo Finance

Novartis (NVS) Has More Growth Ahead. Can its Portfolio Outrun Generic Pressure?

On September 18, Novartis AG (NYSE:NVS) announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for Cosentyx (secukinumab) to treat polymyalgia rheumatica (PMR) in adults who respond inadequately to steroids or relapse during tapering. Following this recommendation, the European Commission is expected to issue a […]

1d agoYahoo Finance

Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?

On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions, including lupus, rheumatoid arthritis, and multiple sclerosis. It happened after three patients died from immune effector cell-associated hemophagocytic syndrome, a rare and severe immune reaction. […]

4d agoYahoo Finance

Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines

Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.

4d agoYahoo Finance

A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team

On September 10, 2026, Reuters reported that Artisan Partners, among Novartis AG (NYSE:NVS)’ 20 largest shareholders, publicly called for a shake-up of the Swiss drugmaker’s board to improve oversight of its acquisitions, after Novartis shares suffered an 11% one-day drop this week. It wiped out nearly $30 billion in market value and erased all of […]

4d agoYahoo Finance

Novartis (SWX:NOVN) Lands Global Radioligand Therapy License To Deepen Cancer Pipeline

Novartis (SWX:NOVN) has signed an exclusive global license agreement with BoomRay Pharmaceuticals for a preclinical radioligand therapy asset. The deal gives Novartis worldwide rights to develop and commercialise the BoomRay program as part of its radiopharmaceutical pipeline. The agreement adds another early stage oncology candidate to Novartis' radioligand therapy efforts, expanding its presence in targeted cancer treatments. This new BoomRay radioligand license sits within a wider pattern...

5d agoYahoo Finance

Also Discussed

Investors talking about NVS also mention

#	Name	Attention
1	Sanofi ADRSNY	0%-0.01
2	Alnylam Pharmaceuticals, Inc.ALNY	0%0
3	GSK plc ADRGSK	0%0
4	Amgen Inc.AMGN	0.01%+0
5	AstraZeneca PLC American Depositary SharesAZN	0.02%+0.02
6	Bristol-Myers Squibb CompanyBMY	0.01%0
7	Merck & Co., Inc.MRK	0.01%-0.06
8	Biogen IncBIIB	0%+0
9	Gilead Sciences, Inc.GILD	0%-0.04
10	Incyte Corp.INCY	0%new

Novartis AG Sponsored ADR

Healthcare
Drug Manufacturers - General

Novartis AG Sponsored ADR represents ownership in Novartis AG, a global healthcare company focused on researching, developing, manufacturing, and marketing innovative medicines. Through this ADR structure, U.S. investors can gain exposure to Novartis AG shares in U.S. dollars, with each depositary receipt backed by an underlying Novartis share held by a depositary bank. Novartis today concentrates on prescription pharmaceuticals across key therapeutic areas such as oncology, cardiovascular, immunology, neuroscience, and ophthalmology, offering treatments for a wide range of chronic and acute conditions. The company’s portfolio includes both established medicines and newer targeted and specialty therapies, supported by significant investment in clinical research and development. Novartis AG Sponsored ADR plays a notable role in the global healthcare sector by providing access to a diversified range of branded drugs that serve hospitals, clinics, and pharmacies worldwide, while giving international investors a convenient mechanism to participate in the performance of a major Swiss-based pharmaceutical company.

Website

Location

Lichtstrasse 35

Basel, 4056

Switzerland

Social

What share of all stock conversation is about NVS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.01% +0.01	0.02% +0.01	0.01% +0

Sep 16

Novartis has acquired Sironax's proprietary brain delivery platform for $125 million, a move that could help the company overcome the blood-brain barrier in its treatments.
Novartis has halted its TREM2 targeting ALS program after a Phase 2 trial failure, marking the company's fourth trial stumble in a month.
Novartis has faced a string of clinical trial failures, including three major setbacks within a single week, which could impact its cardiovascular and other treatment programs.

Generated by AI

Sentiment

Of the messages about NVS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% -100	84.88% +41.41	18.47% -54.95	67.5% -24.1
Bearish	100% new	15.12% -41.41	81.53% +54.95	32.5% +24.1

Bullish· Sep 8

Novartis' growth target may be unattainable without M&A, which could remain a key part of the story for securing management's longer-term mid-single-digit growth aspiration.
The Avidity Biosciences acquisition by $NVS sinks, potentially leading to a gap fill around $133-$135.
Novartis' CEO should consider acquiring companies like Avidity Biosciences, ALT, and SRPT to gain control of the company's future and create value for shareholders.

Bearish· Sep 8

Novartis' ($NVS) del-desiran drug has failed a late-stage trial, missing its primary endpoint and wiping out $20 billion from its market value.
Novartis' ($NVS) second major late-stage trial setback in a matter of days has added pressure on the company, with its shares plummeting nearly 10%.
Novartis' ($NVS) acquisition of Avidity Biosciences for $12 billion may be seen as a costly mistake, with the company's Neuromuscular drug failing in a key study and its peak sales under pressure.

Generated by AI

Topics

Of the messages about NVS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	95.7%	57.06%	48.41%
Analysts	0%	3.23%	16.31%	5.71%
Earnings	0%	0%	0.48%	3.4%
Macro	0%	0%	16.14%	39.31%
Technical Analysis	0%	0%	0.55%	0.86%
Controversies	0%	1.08%	9.45%	2.31%

Earnings· Apr 28

Novartis's Q1 earnings fell short of estimates, with adjusted EPS of $1.99 vs. expected $2.10 and net sales of $13.11B vs. expected $13.36B.
The company's profit was hit by generic competition, which eroded sales of some of its best-selling medicines, including Cosentyx, Kisqali, and Entresto.
Novartis reaffirmed its FY26 guidance, expecting low single-digit growth in net sales and a decline in core operating income.

Analysts· Sep 11

Citigroup upgraded Novartis (NVS) to Buy from Neutral.
Exane BNP Paribas raised Novartis (NVS) to Neutral from Sell.
Novartis (NVS) target price increased to $98.5 by Bank of America.

Announcements· Sep 8

Novartis' del-desiran drug failed to meet its primary endpoint in a Phase 3 trial for myotonic dystrophy type 1, wiping around $20 billion from its market value.
The failure of del-desiran raises serious questions about the strategic rationale behind Novartis' $12 billion Avidity acquisition and the value driver of the drug.
The setback is Novartis' second major late-stage trial failure in a matter of days, and the company's growth target is now perceived as unattainable without further mergers and acquisitions.

Controversies· Jul 2

Novartis has agreed to pay $678 million to settle a long-running case over alleged kickbacks to doctors, resolving speaker program litigation with US authorities.
The settlement follows a court ruling that upheld Amgen's 31-year monopoly on its Enbrel biosimilar, a decision that Novartis had appealed.
The controversy surrounding Novartis' kickback claims has led to a series of settlements, including a previous agreement to pay $51 million+ to resolve allegations that it paid kickbacks through co-pay foundations.

Macro· Jan 6

The US invasion of Greenland could lead to economic sanctions and tariffs, primarily impacting oil, pharmaceuticals, and machinery companies.
Stocks in oil companies, Boeing, Caterpillar, and GE may be heavily affected by such sanctions, while pharmaceutical companies like Pfizer and Eli Lilly may be spared initially.
The potential shift towards European independence from the US could be beneficial for companies like Novartis, Roche, Sanofi, Biontech, Bayer, and FMC.

Generated by AI

Community

Of the messages about NVS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	58.82%	23.71%	54.74%	19.49%
Newcomers	41.18%	76.29%	45.26%	80.51%

Regulars· Sep 10

Major shareholder Artisan Partners is calling for a board shake-up at Novartis due to recent drug trial setbacks, citing failures in acquisitions and a lackluster deal team.
The recent failure of Novartis' Lp(a) trial has raised concerns about the company's ability to reduce cardiovascular outcomes, with LabCorp highlighting the importance of the Lp(a) biomarker.
Novartis could be interested in acquiring CATX, a company that develops a therapy targeting the same receptor as Novartis' established treatment Lutathera, potentially offering stronger tumor killing with a shorter radiation path.

Newcomers· Sep 10

Novartis ($NVS) suffered a record weekly drop after a string of Phase 3 trial setbacks, including a muscle wasting disorder, raising questions about corporate governance and the company's ability to allocate capital effectively.
The recent failure of Novartis' lead drug del-desiran in Phase 3 trials has raised concerns about the company's pipeline value and the potential impact on its market value.
A major Novartis shareholder has called for changes to the company's board to improve corporate governance, and some analysts are now viewing the company's stock as a "capital-allocation story" rather than a traditional drug story.

Generated by AI

Novartis

Social

Sep 16

Bullish· Sep 8

Bearish· Sep 8

Earnings· Apr 28

Analysts· Sep 11

Announcements· Sep 8

Controversies· Jul 2

Macro· Jan 6

Regulars· Sep 10

Newcomers· Sep 10

CAS announces collaboration with Novartis to advance AI-ready reaction informatics

Novartis (NVS) Has More Growth Ahead. Can its Portfolio Outrun Generic Pressure?

Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?

Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines

A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team

Novartis (SWX:NOVN) Lands Global Radioligand Therapy License To Deepen Cancer Pipeline

Also Discussed

Novartis AG Sponsored ADR

Company Information

Location

CAS announces collaboration with Novartis to advance AI-ready reaction informatics

Novartis (NVS) Has More Growth Ahead. Can its Portfolio Outrun Generic Pressure?

Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?

Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines

A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team

Novartis (SWX:NOVN) Lands Global Radioligand Therapy License To Deepen Cancer Pipeline

Also Discussed

Social

Sep 16

Bullish· Sep 8

Bearish· Sep 8

Earnings· Apr 28

Analysts· Sep 11

Announcements· Sep 8

Controversies· Jul 2

Macro· Jan 6

Regulars· Sep 10

Newcomers· Sep 10